Cytokinetics (NASDAQ:CYTK – Get Free Report) was upgraded by Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report issued on Thursday,Benzinga reports. The brokerage ...

A rumor regarding Cytokinetics (CYTK) was highlighted in an alert sent to subscribers of Ben Harrington’s takeover-focused Betaville blog, ...

Morgan Stanley has upgraded Cytokinetics (CYTK) to overweight from equal weight while lowering its price target. Read more ...

Fintel reports that on February 13, 2025, Morgan Stanley upgraded their outlook for Cytokinetics (NasdaqGS:CYTK) from ...

Morgan Stanley analyst Jeffrey Hung upgraded Cytokinetics (CYTK) to Overweight from Equal Weight with a price target of $67, down from $70. The ...

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN ...

Cytokinetics (NASDAQ:CYTK) quickly rose 7.5% amid some renewed takeover speculation. There's some speculation that the company has had some fresh bid interest, according to traders, who cited a ...

Cytokinetics has a 1-year low of $42.72 and a 1-year high of $81.36. The business’s fifty day moving average price is $48.32 and its two-hundred day moving average price is $52.34. Insider ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Kilroy Realty has opened a second phase of its Oyster Point life sciences campus — but it's attracting financial and tech ...